PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Acronyms PERSEUS
- Sponsors Tobira Therapeutics
- 20 Jun 2017 Planned End Date changed from 1 Jun 2017 to 3 Aug 2017.
- 20 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 3 Aug 2017.
- 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.